Skip to Content

Takeda -Launch of Liovel LD And Liovel HD in Japan - Fixed Dose Combination Tablet of Nesina and Actos for Treatment of Type 2 Diabetes

From ENP Newswire (September 21, 2011)

ENP Newswire - 21 September 2011

Release Date- 20092011 - Osaka, Japan, - Takeda Pharmaceutical Company Limited ('Takeda') Announced Today That It Launched LIOVEL, A Fixed Dose Combination Tablet of NESINA (Generic Name: Alogliptin) and ACTOS (Generic Name: Pioglitazone Hcl) for Treatment of Type 2 Diabetes in Japan.

LIOVEL Is A Tablet Taken Orally Once Daily and Has Two Dosage Strengths, 'LIOVEL LD' and 'LIOVEL HD' Which Contain 25mg Alogliptin /15mg Pioglitazone, and 25mg Alogliptin /30mg Pioglitazone Respectively.

NESINA Was Discovered By Takeda's Wholly-Owned Subsidiary, Takeda San Diego, Inc. and Is A Member of the Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Class. It Increases Insulin Secretion and Lowers Blood Glucose Level By Inhibiting DPP-4 Which Is An Enzyme Inactivating Two Hormones [*] Selectively. ACTOS Is A Thiazolidinedione (TZD) Class and Lowers Blood Glucose Level By Improving Insulin Resistance.

'LIOVEL Is the Fixed Dose Combination Tablet of DPP-4 Inhibitors and Thiazolidinedione Launched for the First Time in Japan,' Said Yasuhiko Yamanaka, Managing Director and Senior Vice President of Pharmaceutical Marketing Division. 'LIOVEL Is Expected to Improve the Ease of Administration and Contribute to Better Control of Blood Glucose Levels. We Are Committed to Providing Patients and Healthcare Professionals With Appropriate Information of This Drug.'

the Information Regarding Potential Bladder Cancer Risk Mentioned in the Japanese ACTOS Package Insert Is Reflected Into the LIOVEL Package Insert.

Predicted FY2011 Sale of NESINA Including LIOVEL Is JPY7.5 Billion and Has Been Included in the Projected Consolidated Results for FY2011, Which Was Disclosed on May 11, 2011.

*Glucagon-Like Peptide 1 (GLP-1) and Glucose-Dependent Insulinotropic Peptide (GIP);

GLP-1 and GIP Are Secreted By the Digestive Tract Following Food Intake, and Stimulate the Beta Cells in the Pancreas-Thereby Increasing Insulin Secretion-and They Have the Potential to Improve Pancreatic Beta-Cell Function. Furthermore, It Is Known That Because GLP-1 Suppresses Glucagon Secretion From the Pancreas, It Also Has Functions to Suppress the Production of Sugar in Liver Cells As Well As to Diminish Appetite.

[Editorial Queries for This Story Should Be Sent to Newswire@Enpublishing.Co.Uk]

((Comments on This Story May Be Sent to Info@Enpublishing.Co.Uk))

Posted: September 2011